Fulgent Genetics, Inc. (FLGT)
| Market Cap | 473.89M |
| Revenue (ttm) | 322.67M |
| Net Income (ttm) | -60.51M |
| Shares Out | 30.91M |
| EPS (ttm) | -1.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,620,789 |
| Open | 19.03 |
| Previous Close | 24.76 |
| Day's Range | 15.16 - 19.12 |
| 52-Week Range | 14.57 - 31.04 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 28.33 (+84.8%) |
| Earnings Date | Feb 27, 2026 |
About FLGT
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he... [Read more]
Financial Performance
In 2025, Fulgent Genetics's revenue was $322.67 million, an increase of 13.83% compared to the previous year's $283.47 million. Losses were -$60.51 million, 41.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for FLGT stock is "Buy." The 12-month stock price target is $28.33, which is an increase of 84.80% from the latest price.
News
Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock
Fulgent Genetics offers a fortress balance sheet, zero debt, and net assets near the current share price, providing downside protection. FLGT's diagnostics business is growing, with 15.4% revenue grow...
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development busi...
Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript
Fulgent Genetics, Inc. ( FLGT) UBS Global Healthcare Conference 2025 November 10, 2025 5:00 PM EST Company Participants Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer ...
Fulgent to Participate in Upcoming Conferences
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript
Fulgent Genetics, Inc. ( FLGT) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financi...
Fulgent Reports Third Quarter 2025 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...
Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)
While the stock price is unchanged since my buy rating a year ago, revenue growth is accelerating (FY25E: +14%) and gross margins are going up (FY25E: 40%, +200bps vs PY). Both precision diagnostics a...
Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Brandon Perthuis - Chief Commercial Officer Ming Hsieh - Chairman & CEO Paul Kim -...
Fulgent Reports Second Quarter 2025 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulgent Genetics, Inc. (FLGT) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NA...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...
Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...
Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Investors to Connect
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...
Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...
Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...